Association Between MGMT Promoter Hypermethylation and p53 Mutation in Glioblastoma

REFERENCES

• Reardon D. A., Wen P. Y. Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents. Oncologist 2006; 11(2)152–164
   PubMed Web of Science ®Google Scholar
• Stupp R., Hegi M. E., van den Bent M. J., Mason W. P., Weller M., Mirimanoff R. O., Cairncross J. G. Changing paradigms: an update on the multidisciplinary management of malignant glioma. Oncologist 2006; 11(2)165–180
   PubMed Web of Science ®Google Scholar
• Jemal A., Siegel R., Ward E., Murray T., Xu J., Thun M. J. Cancer statistics, 2007. CA Cancer J Clin 2007; 57(1)43–66
   PubMed Web of Science ®Google Scholar
• Jacinto F. V., Esteller M. Mutator pathways unleashed by epigenetic silencing in human cancer. Mutagenesis 2007; 22(4)247–253
   PubMed Web of Science ®Google Scholar
• Jones P. A., Baylin S. B. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002; 3(6)415–428
   PubMed Web of Science ®Google Scholar
• Yin D., Xie D., Hofmann W. K., Zhang W., Asotra K., Wong R., Black K. L., Koeffler H. P. DNA repair gene O6-methylguanine–DNA methyltransferase: promoter hypermethylation associated with decreased expression and G:C to A:T mutations of p53 in brain tumors. Mol Carcinog 2003; 36(1)23–31
   PubMed Web of Science ®Google Scholar
• Esteller M., Hamilton S. R., Burger P. C., Baylin S. B., Herman J. G. Inactivation of the DNA repair gene O6-methylguanine–DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 1999; 59(4)793–797
   PubMed Web of Science ®Google Scholar
• Hegi M. E., Diserens A. C., Gorlia T., Hamou M. F., de Tribolet N., Weller M., Kros J. M., Hainfellner J. A., Mason W., Mariani L., Bromberg J. E., Hau P., Mirimanoff R. O., Cairncross J. G., Janzer R. C., Stupp R. MGMTgene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352(10)997–1003
   PubMed Web of Science ®Google Scholar
• Wiencke J. K., Aldape K., McMillan A., Wiemels J., Moghadassi M., Miike R., Kelsey K. T., Patoka J., Long J., Wrensch M. Molecular features of adult glioma associated with patient race/ethnicity, age, and a polymorphism in O6-methylguanine–DNA-methyltransferase. Cancer Epidemiol Biomarkers Prev 2005; 14(7)1774–1783
   PubMed Web of Science ®Google Scholar
• Bouchet B. P., de Fromentel C. C., Puisieux A., Galmarini C. M. p53 as a target for anti-cancer drug development. Crit Rev Oncol Hematol 2006; 58(3)190–207
   PubMed Web of Science ®Google Scholar
• Nakamura M., Watanabe T., Yonekawa Y., Kleihues P., Ohgaki H. Promoter methylation of the DNA repair gene MGMTin astrocytomas is frequently associated with G:C →A:T mutations of the TP53 tumor suppressor gene. Carcinogenesis 2001; 22(10)1715–1719
   PubMed Web of Science ®Google Scholar
• Hengstler J. G., Tanner B., Moller L., Meinert R., Kaina B. Activity of O(6)-methylguanine–DNA methyltransferase in relation to p53 status and therapeutic response in ovarian cancer. Int J Cancer 1999; 84(4)388–395
   PubMed Web of Science ®Google Scholar
• Blough M. D., Zlatescu M. C., Cairncross J. G. O 6-methy-lguanine–DNA methyltransferase regulation by p53 in astrocytic cells. Cancer Res 2007; 67(2)580–584
   PubMed Web of Science ®Google Scholar
• Wiewrodt D., Nagel G., Dreimuller N., Hundsberger T., Perneczky A., Kaina B. MGMTin primary and recurrent human glioblastomas after radiation and chemotherapy and comparison with p53 status and clinical outcome. Int J Cancer 2007, 6: 1391–1399
   Web of Science ®Google Scholar
• Herman J. G., Graff J. R., Myohanen S., Nelkin B. D., Baylin S. B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996; 93(18)9821–9826
   PubMed Web of Science ®Google Scholar
• Esteller M., Garcia-Foncillas J., Andion E., Goodman S. N., Hidalgo O. F., Vanaclocha V., Baylin S. B., Herman J. G. Inactivation of the DNA-repair gene MGMTand the clinical response of gliomas to alkylating agents. N Engl J Med 2000; 343(19)1350–1354
   PubMed Web of Science ®Google Scholar
• Paz M. F., Yaya-Tur R., Rojas-Marcos I., Reynes G., Pollan M., Aguirre-Cruz L., Garcia-Lopez J. L., Piquer J., Safont M. J., Balana C., Sanchez-Cespedes M., Garcia-Villanueva M., Arribas L., Esteller M. CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. Clin Cancer Res 2004; 10(15)4933–4938
   PubMed Web of Science ®Google Scholar
• Hegi M. E., Diserens A. C., Godard S., Dietrich P. Y., Regli L., Ostermann S., Otten P., Van Melle G., de Tribolet N., Stupp R. Clinical trial substantiates the predictive value of O 6-methylguanine–DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 2004; 10(6)1871–1874
   PubMed Web of Science ®Google Scholar
• Balana C., Ramirez J. L., Taron M., Roussos Y., Ariza A., Ballester R., Sarries C., Mendez P., Sanchez J. J., Rosell R. O6-methylguanine–DNA methyltransferase methylation in serum and tumor DNA predicts response to 1,3-bis(2-chloroethyl)-1-nitrosourea but not to temozolamide plus cisplatin in glioblastoma multiforme. Clin Cancer Res 2003; 9(4)1461–1468
   PubMed Web of Science ®Google Scholar
• Kaina B., Christmann M., Naumann S., Roos W. P. MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents. DNA Rep. (Amst) 2007; 6(8)1079–1099
   PubMed Web of Science ®Google Scholar
• Esteller M., Risques R. A., Toyota M., Capella G., Moreno V., Peinado M. A., Baylin S. B., Herman J. G. Promoter hypermethylation of the DNA repair gene O(6)-methylguanine–DNA methyltransferase is associated with the presence of G:C to A:T transition mutations in p53 in human colorectal tumorigenesis. Cancer Res 2001; 61(12)4689–4692
   PubMed Web of Science ®Google Scholar
• Zhang Y. J., Chen Y., Ahsan H., Lunn R. M., Lee P. H., Chen C. J., Santella R. M. Inactivation of the DNA repair gene O6-methylguanine–DNA methyltransferase by promoter hypermethylation and its relationship to aflatoxin B1-DNA adducts and p53 mutation in hepatocellular carcinoma. Int J Cancer 2003; 103(4)440–444
   PubMed Web of Science ®Google Scholar
• Lacroix M., Toillon R. A., Leclercq G. p53 and breast cancer: an update. Endocr-Relat Cancer 2006; 13(2)293–325
   PubMed Web of Science ®Google Scholar
• Ohgaki H., Kleihues P. Genetic pathways to primary and secondary glioblastoma. Am J Pathol 2007; 170(5)1445–1453
   PubMed Web of Science ®Google Scholar
• Taylor S. M. p53 and deregulation of DNA methylation in cancer. Cellsci Rev 2006; 2(3)
   Google Scholar